U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H34ClN7O10S2
Molecular Weight 752.215
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFIDEROCOL

SMILES

CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]4(CCNC(=O)C3=C(Cl)C(O)=C(O)C=C3)CCCC4)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5)C(O)=O

InChI

InChIKey=DBPPRLRVDVJOCL-FQRUVTKNSA-N
InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C30H34ClN7O10S2
Molecular Weight 752.215
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 2 / 3
E/Z Centers 1
Optical Activity UNSPECIFIED

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138 mg/L
2 g 3 times / day multiple, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
89.7 mg/L
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1184 mg × h/L
2 g 3 times / day multiple, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
386 mg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Disc. AE: Diarrhea, Drug hypersensitivity...
Other AEs: Diarrhea, Infusion site reactions...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.3%)
Drug hypersensitivity (0.3%)
Hepatic enzymes increased (0.3%)
Death (grade 5, 0.3%)
Other AEs:
Diarrhea (4%)
Infusion site reactions (4%)
Constipation (3%)
Rash (3%)
Candidiasis (2%)
Cough (2%)
Elevated liver enzymes (2%)
Headache (2%)
Hypokalemia (2%)
Nausea (2%)
Vomiting (2%)
Thrombocytosis (<2%)
Congestive heart failure (<2%)
Bradycardia (<2%)
Atrial fibrillation (<2%)
Abdominal pain (<2%)
Dry mouth (<2%)
Stomatitis (<2%)
Pyrexia (<2%)
Peripheral edema (<2%)
Cholelithiasis (<2%)
Cholecystitis (<2%)
Gallbladder pain (<2%)
Drug hypersensitivity (<2%)
Clostridium difficile infection (<2%)
Prothrombin time prolonged (<2%)
Red blood cells urine positive (<2%)
Creatine phosphokinase increased (<2%)
Decreased appetite (<2%)
Hypocalcemia (<2%)
Fluid overload (<2%)
Dysgeusia (<2%)
Seizure (<2%)
Dyspnea (<2%)
Pleural effusion (<2%)
Pruritis (<2%)
Insomnia (<2%)
Restlessness (<2%)
Sources:
1 g 1 times / day single, intravenous
Dose: 1 g, 1 times / day
Route: intravenous
Route: single
Dose: 1 g, 1 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Disc. AE: Urticaria...
AEs leading to
discontinuation/dose reduction:
Urticaria (12.5%)
Sources:
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Disc. AE: Death, Elevated liver enzymes...
Other AEs: Elevated liver enzymes, Hypokalemia...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 26.4%)
Elevated liver enzymes
Other AEs:
Elevated liver enzymes (16%)
Hypokalemia (11%)
Diarrhea (9%)
Hypomagnesemia (5%)
Atrial fibrillation (5%)
Thrombocytopenia (<4%)
Thrombocytosis (<4%)
Myocardial infarction (<4%)
Atrial flutter (<4%)
Nausea (<4%)
Vomiting (<4%)
Abdominal pain (<4%)
Cholecystitis (<4%)
Cholestasis (<4%)
Clostridium difficile infection (<4%)
Oral candidiasis (<4%)
Prothrombin time prolonged (<4%)
Activated partial thromboplastin time (<4%)
Hypocalcemia (<4%)
Hyperkalemia (<4%)
Seizure (<4%)
Acute interstitial nephritis (<4%)
Cough (<4%)
Rash (<4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Drug hypersensitivity 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Hepatic enzymes increased 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Candidiasis 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Cough 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Elevated liver enzymes 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Headache 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Hypokalemia 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Nausea 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Vomiting 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Constipation 3%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Rash 3%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Diarrhea 4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Infusion site reactions 4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Abdominal pain <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Atrial fibrillation <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Bradycardia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Cholecystitis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Cholelithiasis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Clostridium difficile infection <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Congestive heart failure <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Creatine phosphokinase increased <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Decreased appetite <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Drug hypersensitivity <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Dry mouth <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Dysgeusia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Dyspnea <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Fluid overload <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Gallbladder pain <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Hypocalcemia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Insomnia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Peripheral edema <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Pleural effusion <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Prothrombin time prolonged <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Pruritis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Pyrexia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Red blood cells urine positive <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Restlessness <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Seizure <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Stomatitis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Thrombocytosis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Death grade 5, 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
Health Status: unhealthy
Age Group: 18 to 93 years
Sex: M+F
Sources:
Urticaria 12.5%
Disc. AE
1 g 1 times / day single, intravenous
Dose: 1 g, 1 times / day
Route: intravenous
Route: single
Dose: 1 g, 1 times / day
Sources:
unhealthy, mean age 60.1 years
Health Status: unhealthy
Age Group: mean age 60.1 years
Sex: M+F
Sources:
Hypokalemia 11%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Elevated liver enzymes 16%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Atrial fibrillation 5%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Hypomagnesemia 5%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Diarrhea 9%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Abdominal pain <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Activated partial thromboplastin time <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Acute interstitial nephritis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Atrial flutter <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Cholecystitis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Cholestasis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Clostridium difficile infection <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Cough <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Hyperkalemia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Hypocalcemia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Myocardial infarction <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Nausea <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Oral candidiasis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Prothrombin time prolonged <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Rash <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Seizure <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Thrombocytopenia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Thrombocytosis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Vomiting <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Elevated liver enzymes Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
Death grade 5, 26.4%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
Health Status: unhealthy
Age Group: median age - 67 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
Drug as victimTox targets

Tox targets

Substance Class Chemical
Created
by admin
on Mon Mar 31 23:20:52 GMT 2025
Edited
by admin
on Mon Mar 31 23:20:52 GMT 2025
Record UNII
SZ34OMG6E8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFIDEROCOL
INN   WHO-DD  
INN  
Official Name English
GSK-2696266
Preferred Name English
(6R,7R)-7-[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Systematic Name English
CEFIDEROCOL [MI]
Common Name English
RSC649266
Code English
S-649266
Code English
PYRROLIDINIUM, 1-(((6R,7R)-7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-((1-CARBOXY-1-METHYLETHOXY)IMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-(2-((2-CHLORO-3,4-DIHYDROXYBENZOYL)AMINO)ETHYL)-, INNER SALT
Systematic Name English
GSK2696266
Code English
RSC-649266
Code English
S649266
Code English
CEFIDEROCOL [USAN]
Common Name English
Cefiderocol [WHO-DD]
Common Name English
cefiderocol [INN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548666
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
LIVERTOX NBK547862
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
Code System Code Type Description
DRUG CENTRAL
5352
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
MERCK INDEX
m12179
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
RXCUI
2265702
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
NCI_THESAURUS
C169831
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
DAILYMED
SZ34OMG6E8
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
WIKIPEDIA
Cefiderocol
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
INN
10234
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
DRUG BANK
DB14879
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
FDA UNII
SZ34OMG6E8
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
CHEBI
140376
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
LACTMED
Cefiderocol
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
SMS_ID
100000175826
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
EPA CompTox
DTXSID401098052
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
CAS
1225208-94-5
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
USAN
EF-99
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
PUBCHEM
77843966
Created by admin on Mon Mar 31 23:20:52 GMT 2025 , Edited by admin on Mon Mar 31 23:20:52 GMT 2025
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
BINDER->LIGAND
Primarily to albumin
BINDING
TARGET ORGANISM->INHIBITOR
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC